CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
IPO Year: 2025
Exchange: NYSE
Website: capps.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2026 | $26.00 | Outperform | Robert W. Baird |
| 12/2/2025 | $28.00 | Hold | Canaccord Genuity |
| 7/14/2025 | $31.00 | Buy | BofA Securities |
| 7/14/2025 | $31.00 | Overweight | Analyst |
| 7/14/2025 | $32.00 | Buy | Guggenheim |
| 7/14/2025 | $33.00 | Outperform | Evercore ISI |
| 7/14/2025 | $32.00 | Buy | TD Cowen |
| 7/14/2025 | $38.00 | Buy | BTIG Research |
| 7/14/2025 | $34.00 | Buy | Citigroup |
| 7/14/2025 | $32.00 | Outperform | Wolfe Research |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Robert W. Baird initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $26.00
Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00
BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00
Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00
Guggenheim initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00
Evercore ISI initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $33.00
TD Cowen initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00
BTIG Research initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $38.00
Citigroup initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $34.00
Wolfe Research initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $32.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)
SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)
10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
Fastest customizable press release news feed in the world
In the news release, Caris Life Sciences Completes Interim Readout of Achieve 1 Study, issued 26-Feb-2026 by Caris Life Sciences over PR Newswire, we are advised by the company that PR Newswire incorrectly placed the second line of the headline as a sub-headline. The complete, corrected release follows, with additional details at the end: Caris Life Sciences Completes Interim Readout of Achieve 1 Study Demonstrates Superior Sensitivity and Specificity of Caris Detect Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation
Demonstrates Superior Sensitivity and Specificity of Caris DetectResults demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular ins
Full year revenue growth of 97% driven by strong performance in molecular profiling servicesExpects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billionIRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsReported total revenue of $292.9 million, an increase of 125% over the corresponding prior year period
IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that provides an additional tumor biology resource and is available upon request when ordering MI Cancer Seek®. The Caris AI Insights section of the Caris Molecular Tumor Board Report includes signatures power
IRVING, Texas, Feb. 23, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through c
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. This study explains why patient responses vary and reveals how resistance can evolve over time.
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximatel
IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers. Caris and Everlywell are partnering to launch Caris Detect™, Caris' forthcoming Multi-Cancer Early Detection (MCED) blood-based screening assay, through Everlywell's platform
IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California. Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com. About Caris Life Sciences Ca
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
Live finance-specific insights
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will
IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a
CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co
Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count
CAI International, Inc. ("CAI" or the "Company") (NYSE:CAI), one of the world's leading transportation finance companies, today reported results for the first quarter of 2021. Highlights Net income from continuing operations attributable to CAI common stockholders for the first quarter of 2021 was $32.5 million, or $1.85 per fully diluted share. Return on common equity on adjusted net income from continuing operations1 was 21.3% in the first quarter of 2021. Total leasing revenue for the first quarter of 2021 was $80.8 million, compared to $69.1 million in the first quarter of 2020. CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on June 25, 2021
SAN FRANCISCO--(BUSINESS WIRE)--CAI International, Inc. (“CAI” or the “Company”) (NYSE: CAI), one of the world’s leading transportation finance companies, today reported results for the fourth quarter and full year of 2020. Highlights Net income from continuing operations attributable to CAI common stockholders for the fourth quarter of 2020 was a record $32.5 million, or $1.81 per fully diluted share. Adjusted net income from continuing operations attributable to CAI common stockholders1 for the fourth quarter of 2020 was also a record at $31.6 million, or $1.76 per fully diluted share. Return on equity on adjusted net income from continuing operations1 was 21.2% in the fo
This live feed shows all institutional transactions in real time.
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13D - CAI International, Inc. (0001388430) (Subject)
SC 13D/A - CAI International, Inc. (0001388430) (Subject)
SC 13D/A - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)